A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people.
Eisai Co., Ltd. based in Tokyo, Japan is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
HLL Biotech Limited (HBL) is a 100% subsidiary of HLL Lifecare Limited, a Mini Ratna Schedule B Central Public Sector Enterprise under the Ministry of Health & Family Welfare. HBL is setting up a vaccine complex at Chengalpett, Chennai for manufacturing of Bacterial and Viral Vaccines & developing a strong R&D base for vaccine technologies within the country.
HLL Lifecare Limited is a Mini Ratna Company of Govt. of India under the Ministry of Health & Family Welfare. HLL, a schedule B Public Sector Enterprise, is today a multi product, multi location organization addressing various public health challenges.
Indian Drugs and Pharmaceuticals Limited (IDPL) is a Central Public Sector Undertaking wholly owned by the Government of India engaged in manufacture of pharmaceuticals with plants at Rishikesh, Gurgaon & Hyderabad and two Subsidiary Units at Chennai and Muzaffarpur.
Multani Research Foundation was established with an objective to develop & deliver best Quality Drugs affordable by needed ones based on scientific rationale and knowledge of Ayurveda. To meet its expansion plan in the area of new range of FMCG and Herbal Drugs development required following personnel.
Torrent Pharmaceuticals Limited, is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.
Emcure are fortunate to have a very passionate and talented team. Emcure is committed to emerge as the most preferred employer. We have conducted several training programs and also taken policy decisions towards creating a better work life balance for our people. One of our strengths has been our decentralized approach to managing the business, which is a tremendous magnet for talent – this approach gives people room to grow and room to explore new ideas, thus developing their own skills and careers.
*Sunil kumar, Amit kumar shahi, Ravi shanker, R. singh, Dr. R. ParthSarthy, Dr S.K. Prajapati
Kamla Nehru institute of technology and management, Sultanpur.
Bundelkhand university, Department of pharmacy, Jhansi
The purpose of this research is to design proniosomal powder drug delivery system of flurbiprofen in a trial to overcome the adverse effects associated with oral administration of the drug. Conventional chemotherapy for the treatment of intracellular infection is no more effective due to limited permeation of drug into cell. This can be overcome by the use of vesicular drug delivery system. Encapsulation of a drug in vesicular structure can be predicted to prolong the existence of the drug in the systemic circulation and thus enhance penetration into target tissue and reduce toxicity.Proniosomal powder are generally present in transparent, translucent or white texture, which makes them physically stable during storage and transport. Due to the limited solvent system present, the proniosomes formed were the mixture of many phases of liquid crystal, viz. lamellar, hexagonal and cubic phase liquid crystals.The potential of proniosomes as a transdermal drug delivery system for flurbiprofenwas investigated by encapsulating the drug in various formulations of proniosomal powder composed of various ratios of sorbitan fatty acid esters, cholesterol, prepared by slurry method. The formulated systems were characterized in vitro for size, vesicle count, drug entrapment, drug release profiles and vesicular stability at different storage conditions. Stability studies for proniosomal powder were carried out for 4 weeks. The method of proniosome loading resulted in an encapsulation yield of 30.6 – 75.4%. Proniosomes were characterised by transmission electron microscopy. In vitro studies showed prolonged release of entrapped flurbiprofen. At refrigerated conditions, higher drug retention was observed. It is evident from this study that proniosomes are a promising prolonged delivery system for captopril and have reasonably good stability characteristics.